Darvocet (Propoxyphene/Acetaminophen) Is No Longer Available
Darvocet and all propoxyphene-containing products were permanently withdrawn from the U.S. market in November 2010 due to fatal cardiac arrhythmias, and you should not attempt to obtain or use this medication. 1
Why Propoxyphene Was Removed
The FDA mandated withdrawal because propoxyphene causes:
- Fatal cardiac toxicity including QTc prolongation and arrhythmias
- Cardiotoxic effects from norpropoxyphene (a non-opioid metabolite)
- Deaths that far outweighed any therapeutic benefit 2
Research consistently demonstrated that propoxyphene was no more effective than acetaminophen alone for pain relief, yet carried significant opioid-related risks including respiratory depression, addiction potential, and the cardiac dangers mentioned above 3, 2, 4.
Safe Discontinuation Strategy (If Somehow Still Taking)
If a patient is somehow still taking propoxyphene from old supplies, discontinuation must be gradual to prevent opioid withdrawal syndrome 1:
Tapering Protocol:
- Reduce dose by 25-50% per day while monitoring for withdrawal symptoms 1
- If withdrawal symptoms emerge (restlessness, anxiety, muscle aches, insomnia, GI distress, increased vital signs), increase back to previous dose and taper more slowly 1
- Either increase the interval between dose reductions or decrease the amount of each reduction 1
Withdrawal symptoms to monitor: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, mydriasis, irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, vomiting, diarrhea, elevated blood pressure/heart rate 1
Alternative Analgesic Selection
First-Line: Acetaminophen
Start with acetaminophen as first-line therapy for mild-to-moderate pain, particularly for osteoarthritis-related pain 4, 5:
- Equally effective as propoxyphene was (and propoxyphene was no better than acetaminophen anyway)
- Recommended by American College of Rheumatology as first-line for OA pain 4
- Maximum dose: 4 grams daily (3 grams in elderly, malnourished, or liver disease patients) 5
- Fast-dissolving formulations provide superior pain relief 5
Second-Line Options
Tramadol is the preferred next step for patients requiring more than acetaminophen but at risk for NSAID toxicity 4:
- Effective for moderate pain
- Lower risk profile than traditional opioids
- Particularly useful in elderly patients who cannot tolerate NSAIDs
NSAIDs (use cautiously):
- Consider only in younger patients without GI/renal/cardiovascular risk factors
- Avoid in elderly due to GI bleeding, renal toxicity, and cardiovascular risks 4
- If used, employ lowest effective dose for shortest duration
Other opioids (hydrocodone, oxycodone):
- Reserve for severe pain unresponsive to non-opioid options
- Following propoxyphene withdrawal, hydrocodone and tramadol were the most common substitutes 6
- Must follow CDC 2022 opioid prescribing guidelines 7
If Prescribing Opioids
Per CDC 2022 guidelines, you must 7:
- Set realistic expectations: complete pain elimination is unlikely; focus on functional improvement
- Discuss serious risks: respiratory depression, opioid use disorder, death at higher doses
- Warn about CNS depression with concurrent benzodiazepines, alcohol, or other sedatives
- Prescribe naloxone for overdose reversal
- Use PDMP monitoring and toxicology screening
- Plan for periodic reassessment and potential tapering
Critical Pitfalls to Avoid
- Do not abruptly discontinue opioids in dependent patients - this precipitates withdrawal and increases risk of adverse events including seeking illicit opioids 8
- Do not exceed 4g daily acetaminophen - hepatotoxicity risk, especially when combining multiple acetaminophen-containing products 7, 1
- Do not assume propoxyphene was effective - it wasn't, so simpler alternatives like acetaminophen alone are appropriate 3, 2
- Avoid rapid tapers - research shows each additional week of taper time reduces adverse events by 7% 8
Real-World Context
After the 2010 withdrawal, 34% of propoxyphene users discontinued all opioids entirely, while most others transitioned to tramadol or hydrocodone 6. Importantly, adverse events did not increase after the withdrawal, supporting that propoxyphene provided minimal benefit 6. The prevalence of propoxyphene in workplace drug testing has appropriately declined to near-zero 9.